Abstract
Immune checkpoint inhibitors (ICIs), as a revolutionary new immunotherapy therapy, can improve the survival of cancer patients. Nevertheless, ICIs are only effective for some patients. Therefore, there is an urgent need to explore biomarkers that can predict prognosis in cancer patients treated with ICIs. Neurotrophin tyrosine kinase receptor 3 (NTRK3) acts as a tumor suppressor or oncogene in the development of various cancers. However, the efficacy of NTRK3 mutation in immunotherapy for patients with cancer is unknown.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
